In both private sessions and group calls with my T1D clients, medications like Ozempic, Mounjaro, and other GLP-1 or dual GIP/GLP-1 agonists come up a lot. They’re everywhere right now.
Most of what we know about these medications comes from research in people with Type 2 diabetes—but a new study finally looked at what happens when people with Type 1 use them.
Published in Diabetes, Obesity and Metabolism (October 2024), this real-world study followed adults with T1D and insulin resistance or weight concerns for 12 months.
Here’s what stood out:
- Tirzepatide: ~11 % average weight loss
- Semaglutide: ~10 %
- Liraglutide: ~7 %
- A1C: modest improvement (0.2–0.6 %)
- No increase in severe lows or DKA
The takeaway? These medications can be safe and helpful tools for some people with T1D who are working on weight or metabolic health. But they’re not a magic fix—and the improvements were smaller than what’s typically seen in Type 2.
That’s an important reminder that what we do every day still matters most:
- Eating real, balanced meals that stabilize glucose
- Building and protecting muscle (the #1 predictor of longevity)
- Supporting gut health and lowering inflammation
- Managing stress, sleep, and hydration to boost insulin sensitivity
If you’re exploring medications like these, start by strengthening your foundation first. When your nutrition, muscle health, and stress balance are solid, tools like GLP-1s tend to work better—and your results last longer.
It’s the same approach I teach inside my GRACE Method and Cleanse programs: stabilize blood sugar, protect muscle, and build a metabolism that supports you for the long run.
Bottom line: this new study supports what I see every day in practice—when Type 1s focus on the foundations, the body responds beautifully. Medications can help, but your daily habits are what move the needle.
If you’re interested in learning more about how to optimize your nutrition, digestion, and blood sugars to get the most from tools like these medications—or even supplements such as the new CaloCurb Clinical—let’s connect.
